HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German OTC Marketing News: GSK Knee Brace, J&J Pharmacy Comp, Teva Paracetamol Boost

Executive Summary

The latest marketing news from Europe’s largest OTC market: GSK Consumer Healthcare adds a drug-free knee and ankle support to its Voltaren line; J&J Consumer Health challenges German pharmacists to create attractive displays for its Dolormin Extra analgesic; Teva’s Ratiopharm subsidiary boosts paracetamol with brown algae, plus more.

You may also be interested in...



DACH Q2 Wellness Launches: Bayer Austria Supports Athletes, P&G And Hevert Help Germans Sleep

A round-up of recent dietary supplement launches in the DACH region (Germany, Austria and Switzerland). Bayer Austria rolls out a new sports supplement; P&G brings its ZzzQuil sleep aid supplements to Germany and Austria; Hevert adds two German supplement sprays, one for sleep one for immunity.

Clean Sweep For German Rx-To-OTC Switches Of Next-Gen Pain And Cough Treatments

Germany’s Expert Committee for Prescription has recommended three novel Rx-to-OTC switch applications: analgesics dexibuprofen and ibuprofen/paracetamol single-pill combinations, and cough treatment levodropropizine.

Common Dietary Supplement Additive Ruled Unsafe By EU Regulator

Titanium dioxide - used as a colorant in many dietary supplements - is no longer considered safe when used as a food additive, says the European Food Safety Authority. The European Commission and EU member states must now decide whether to follow France's lead and ban its use in foods outright. 

Topics

UsernamePublicRestriction

Register

RS151739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel